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Regulation of mesangial cell proliferation. Regardless of the in the control of MC proliferation appears to play an
source of injury, an imbalance in the control of mesangial cell early and crucial role in the pathogenesis of progressive
proliferation appears to play a direct role in the degree of glomerular injury and glomerulosclerosis. In experimen-progressive renal injury and glomerulosclerosis. Some of the
tal models of nephritis, MC proliferation frequently pre-regulatory mechanisms include specific soluble or non-soluble
cedes and is linked to the increase of extracellular matrixextracellular factors and a complex array of receptor-mediated
signals that control the progression of the cell cycle or cell (ECM) in the mesangium and glomerulosclerosis [2, 3].
death. Understanding these regulatory processes could lead to For example, mice transgenic for the SV40 T antigen,
novel therapeutic strategies to alleviate or arrest proliferative which has growth-promoting functions, develop MC pro-glomerular disease.
liferation followed by progressive sclerosis [4], and mice
transgenic for growth hormone ultimately develop se-
vere progressive mesangial sclerosis. They show a five-In the adult organism, normally quiescent cells exhibit
fold increase in the 3H-thymidine–labeling index of glo-increased replication rates during tumorigenesis or in
merular cells. Interestingly, the labeling index remainedthe tissue repair processes following injury. In the renal
high at late time points in densely sclerotic glomeruliglomerulus, very different types of injury are able to
[2], indicating that increased MC turnover can be a sig-induce local inflammatory reactions involving resident
nificant feature associated with sclerosis, both at the on-glomerular cells. Lesions may be immune mediated, in-
set and in later stages.fectious, toxic, mechanical, or of other etiologies. A
Moreover, measures that reduce cell proliferation inprominent histopathological feature of many human and
glomerular disease models, such as treatment with hepa-experimental glomerular inflammatory diseases is cellu-
rin [5], low-protein diet [6], or neutralizing antibodies tolar hyperplasia in the mesangium, which is caused by
platelet-derived growth factor (PDGF) [7], have beenproliferation of mesangial cells (MCs) and an influx of
shown to reduce ECM expansion and sclerotic changes.leukocytes (Fig. 1). In this article we discuss the patho-
Further evidence for the role of uncontrolled MC prolif-physiological relevance of increased MC proliferation in
eration in the pathogenesis of glomerulosclerosis wasthe context of glomerular disease progression and review
provided by work of Pippin et al, who studied the effectssome of the extracellular factors and molecular mecha-
of the pharmacological cdk2 inhibitor roscovitine on dis-nisms controlling MC growth.
ease progression in mesangioproliferative anti-Thy1.1
nephritis of the rat [8]. The application of the purine
RELEVANCE OF INCREASED MESANGIAL analogue roscovitine resulted in a significant reduction of
CELL PROLIFERATION
MC proliferation and glomerular cellularity in nephritic
Pathogenetic linkage of mesangial cell hyperplasia and animals. Notably, the decrease of MC replication was
glomerulosclerosis associated with a marked reduction of mesangial ECM
Because proliferation of MCs in the normal adult kid- accumulation and less deposition of collagen type IV,
ney is tightly regulated with a growth rate of less than laminin, and fibronectin [8].
1% [1], quiescent MCs can be assumed to interact with
Reconstitutive mesangial cell proliferation inno or few mitogens and/or to be protected by either
glomerular repairdown-regulation of receptors or the presence of growth-
inhibitory factors maintaining the low proliferative activ- Persistent MC hyperplasia caused by repetitive or con-
ity. Regardless of the injurious mechanism, an imbalance tinuous glomerular injury is thought to precede and lead
to irreversible glomerular scarring and the loss of renal
function. However, like in regular wound healing, theKey words: glomerulosclerosis, hyperplasia, tumorigenesis, injury, in-
flammation, lesions. transient increase of MC proliferation presumably re-
flects a physiological response required for successful 1999 by the International Society of Nephrology
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Fig. 1. Immunohistochemical detection of the proliferation marker, proliferating cell nuclear antigen (PCNA), and the G1 phase-regulatory
protein cyclin D1 in rat kidney sections from normal control animal and five days after the induction of mesangioproliferative anti-Thy1.1 nephritis.
PCNA-positive and cyclin D1-positive nuclei are stained black.
glomerular reconstitution and renal tissue repair. Evi- loss of MCs, such as anti-Thy1.1 nephritis [9] or Habu
toxin glomerulopathy [10], exhibit marked proliferationdence for this concept comes from observations in sev-
eral types of human glomerular diseases, for example, of MCs leading to transient MC hyperplasia and matrix
accumulation. If no repetitive insult to the mesangium ispoststreptococcal glomerulonephritis and some forms of
lupus nephritis. These diseases show marked expansion added in these animals, both diseases show spontaneous
repair of the glomerular tufts within a few weeks, indicat-of the mesangium because of MC hyperplasia, which may
subsequently resolve completely once the inflammatory ing that early and pronounced MC replication may in-
deed be part of the physiological reconstitutive responsecause has subsided. In addition, experimental animal
models of mesangiolytic injury characterized by a rapid of glomeruli to injury, such as mesangiolysis. Thus, thera-
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Fig. 2. Schematic illustration of two types of mesangial cell (MC) proliferation in glomerulonephritis and in homeostatic remodeling: “reconstitutive”
proliferation of remaining MCs following mesangiolysis or “nonreconstitutive” MC replication after the activation of orthotopic MCs without
prior cell loss. Defective homeostatic mechanisms are associated with extracellular matrix (ECM) accumulation and glomerular scarring.
peutical manipulations aiming to block MC mitogenesis can distinguish between “reconstitutive” proliferation of
could represent a double-edged sword. Although the the remaining MCs after mesangiolysis from “nonre-
available evidence suggests that control of overshooting constitutive” or “orthotopic” MC replication in response
MC replication is beneficial in reducing ECM accumula- to activation of intact MCs, for example, by soluble
tion, interference with reconstitutive proliferation of growth factors. However, it should be noted that in vivo
MCs could conceivably lead to incomplete cellular re- these histological features may occur simultaneously,
population of the glomerular tuft and defective repair. even within the same glomerulus. Currently, the method-
Clearly, more precise markers than MC hyperplasia are ology is insufficient to discern the nature of the prolifera-
needed to better characterize the dynamic nature of MC
tive processes in glomerulonephritis. This problem isproliferation and its regulators in proliferative glomeru-
aggravated in the evaluation of human glomerular dis-lonephritis. This would also allow a more rational evalua-
eases because of the fact that a regular kidney biopsytion of the effects of growth-inhibitory manipulations in
specimen yields but a limited number of tissue sectionsproliferative glomerular diseases following the loss of
with rather few glomeruli. Currently, these limitationsMCs and in chronic-progressive disease stages. Figure 2
prevent thorough and meaningful studies of glomerularschematically depicts two types of increased MC prolifer-
ation in response to glomerular injury. Conceptually, one cell turnover in patients.
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Apoptosis: A clearing mechanism balancing mesangial in this model is associated with significant and transient
increases of cyclin A and cdk2 protein [20]. Moreover,cell hyperplasia
the increase of cdk2 protein expression in the course ofWhen recovery of mesangioproliferative disease oc-
nephritis correlated with an increase of cdk2 activity, ascurs, how is the resolution of hypercellularity achieved?
measured by histone H1 kinase assay in isolated glomer-Theoretically, resolution would require the reduction of
uli. In normal rat glomeruli, the expression of the CKIthe baseline regeneration or proliferation rate and/or
p27Kip1 was high, whereas the levels of p21Waf-1 were low.increased removal or death of MCs. Recent research has
The onset of MC proliferation in the anti-Thy1.1 modelexamined cell apoptosis, a process that uses a controlled
was associated with a reduction of p27Kip1 levels. Theprogram to achieve cell death. In glomeruli, apoptotic
resolution of MC proliferation was associated with abodies can be found in renal biopsies from patients with
return to baseline levels for p27Kip1, whereas the expres-proliferative glomerulonephritis [11]. Baker et al and
sion for p21Waf-1 further increased and remained elevatedShimizu et al demonstrated that MC apoptosis is a cell
following the resolution of proliferation [20]. The rele-clearance mechanism counterbalancing MC division in
vance of the sustained p21Waf-1 was not fully explained,self-limited anti-Thy1.1 glomerulonephritis, thereby con-
but one could speculate that p21Waf-1 has a functionaltributing to the resolution of glomerular hypercellularity
role in the long-term resolution of mesangioproliferativecaused by experimentally induced MC proliferation in
disease. Currently, however, this interpretation is un-rats [12, 13]. In these experiments, mitotic and apoptotic
proven.cells were detected in the same glomerulus, suggesting
Indeed, recent data have shown that p21Waf-1 has diver-that both processes can occur simultaneously. Although
gent functions. The CKI p21Waf-1 can act as an assemblythese studies imply a beneficial role of apoptosis as a
factor of cdk4/cyclin D complexes or as an inhibitor ofmechanism leading to the reduction of MC hyperplasia
CDK/cyclin complexes [16, 21]. We have recently exam-and thereby contributing to the resolution of glomerular
ined how soluble regulators of MC growth affect p21Waf-1disease, other data indicate that excessive apoptosis can
expression in cultured MCs. We found that PDGF causesbe harmful, leading to glomerular hypocellularity [14].
a marked increase of p21Waf-1 protein in MCs [22]. TheAgain, these observations reflect the fact that glomerular
induction of p21Waf-1 protein by PDGF was also reportedMC numbers at any given stage during glomerular dis-
in p53-deficient as well as in normal mouse fibroblasts,ease are determined by the rates of cell proliferation and
supporting the interpretation of p53-independent up-loss. Clearly, homeostatic reconstitution of the glomeru-
regulation of p21Waf-1 by PDGF [23]. In other cell types,lus depends on a regulated balance between these two
the growth-inhibitory cytokine transforming growth fac-processes. The precise mechanisms controlling the glo-
tor-b1 (TGF-b1) was found to enhance p21Waf-1 expres-merular cell turnover and net cell number in health and
sion by p53-independent mechanisms [24]. However, ourdisease are currently incompletely understood.
experiments showed that in cultured rat MCs, TGF-b1
led to a slight reduction of the p21Waf-1 expression, which
MOLECULAR CONTROL OF MESANGIAL was induced by PDGF [22], whereas it strongly stimu-
CELL CYCLE PROGRESSION lated p27Kip1. These divergent findings indicate that the
nature of TGF-b1–mediated effects on cell cycle regula-The division cycle of eukaryotic cells is controlled by
a series of checkpoints and transitions in which temporal tory proteins differs considerably between cell types.
In our studies, we observed that increased nuclearorder is imposed by cyclin-dependent kinases (CDKs),
acting in concert with their regulatory subunits, the abundance of cyclin D1 protein in MCs precedes the
peak of MC hypercellularity in anti-Thy1.1 glomerulone-cyclins (Fig. 3) [15]. Cyclin kinase inhibitors (CKIs), such
as p21Waf-1, p27Kip1, and members of the INK4 family of phritis (Fig. 1), suggesting its involvement in the develop-
ment of mesangioproliferative disease [22]. To furtherCDK inhibitors, negatively regulate the cell cycle by
inhibiting the formation or activation of cyclin-CDK examine the relevance of the in vivo finding of enhanced
cyclin D1 expression for MC hyperplasia, we studied thecomplexes [16]. In the past few years, considerable ad-
vances have been made in this field of research, and effects of soluble regulators of MC growth on cyclin
D1 expression in vitro. In growth-arrested rat MCs innephrologists are applying this knowledge to elucidate
the molecular control of cell cycle progression of renal culture, mitogenic stimulation with serum or PDGF
led to a rapid increase of cyclin D1 protein expression.cells, including MCs. New findings on molecular mecha-
nisms of cell cycle control were presented at this sympo- TGF-b1 inhibited PDGF-related induction of cyclin D1
protein. Because cyclin D1 is a key regulator of earlysium and are the subject of recent reviews [16–19].
The rat anti-Thy1.1 model of mesangioproliferative G1-phase progression and adenovirus-mediated overex-
pression of cyclin D1 in MCs increased MC mitogenesisglomerulonephritis has been used to study the in vivo
expression of cell cycle regulators in glomerular cells. [25], we examined whether the reduction of cyclin D1
protein abundance by transfection of antisense oligonu-Shankland et al showed that the onset of MC replication
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Fig. 3. Schematic diagram of the signaling pathway that mediates cell cycle progression through the G1 into the S phase. Cell cycle progression
is controlled by cyclin-dependent kinases (CDK) and their regulatory subunits, the cyclins. Nuclear kinase inhibitors (for example, p15, p16, p21,
and p27) modulate the enzymatic activity of cyclin/CDK complexes. External (for example, TGF-b, PDGF, collagen I) or internal regulators
(for example, p53) influence the activity and/or expression of these inhibitors. The transcription factor E2F is repressed by its binding to the
underphosphorylated form of the retinoblastoma gene product (pRb). Phosphorylation of pRb activates E2F, which induces the transcription of
target genes essential for G1 and S phase progression. The abortion of G1 phase progression may result in apoptosis or allow for DNA repair.
The restriction point (R) in the late G1 phase is where cells commit to completing the cell cycle.
cleotides (ODNs) is sufficient to inhibit cdk4 kinase ac- gies aiming to reduce cyclin D1 expression, for example,
by transfer of antisense ODNs or by specific cyclin antag-tivity and MC proliferation. Several studies successfully
employed transfection of antisense ODNs to examine onists, might represent an effective means to inhibit MC
proliferation in vivo.the roles of MC growth regulators and to block MC
replication. In cultured MCs, proliferation could be in- Other studies investigated whether or not MC replica-
tion is reduced by suppressing the activity of transcrip-hibited by using antisense ODNs against the early growth
response gene Egr-1 [26] or other cell cycle-associated tion factor E2F. E2F controls the expression of several
genes involved in cell cycle progression, including c-myc,proteins such as PCNA or Ki-67 [27]. We observed that
antisense ODNs against cyclin D1 reduced the serum- c-myb, proliferating cell nuclear antigen (PCNA), and
cdk2 kinase [19]. In order to inhibit E2F, decoy ODNsor PDGF-induced protein expression of cyclin D1 to
48% or 10% of control levels, respectively [22]. These that contained the consensus E2F binding site sequence
as a competitive inhibitor were transfected. Transfectioninhibitory effects correlated with diminished cdk4 activ-
ity. Subsequently, the MC proliferation caused by serum of E2F decoy ODNs effectively reduced the proliferation
of serum-stimulated MCs in vitro [29]. Moreover, an inor PDGF was markedly inhibited by antisense ODNs
against cyclin D1, as measured by [3H]-thymidine uptake vivo tranfection of E2F decoy ODNs into rat kidneys 36
hours after the induction of anti-Thy1.1 suppressed MCand MC counts. Antisense ODNs against cyclin D1 have
also been shown to diminish the increase of DNA synthe- proliferation by 71% [30]. These results correlated with
reduced glomerular expression of PCNA [30], indicatingsis of rat MCs induced by endothelin-1 [28]. Thus, strate-
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that decoy ODNs can inhibit the activity of E2F and by which cdk2 activity is negatively regulated by TGF-
b1 in MCs.may have the potential to treat proliferative forms of
glomerulonephritis. Transforming growth factor-b1 has also been reported
to cause hypertrophy of renal cells, including renal epi-
thelial cells [41] and MCs [42, 43]. Work by Wolf et al
TRANSFORMING GROWTH FACTOR-b: AN
has identified the CKI p27Kip1 as an important mediator
AUTOCRINE INHIBITOR OF MESANGIAL
of high-glucose-induced hypertrophy of MCs [44, 45].
CELL REPLICATION
Medium containing high d-glucose (450 mg/dl) stimu-
In vitro and in vivo studies have identified a multitude lated the expression of p27Kip1 protein in cultured MCs.
of extracellular factors that stimulate or inhibit MC pro- This induction of p27Kip1 involved activation of protein
liferation, including various soluble cytokines, autacoids, kinase C and was at least partly dependent on autoinduc-
hormones, as well as insoluble ECM molecules. Many of tion of TGF-b in MCs [45]. Moreover, studies in the db/db
these ligands are produced by MCs and possess autocrine mouse model of diabetes type II revealed an increase
growth-modulating activities [31]. Although numerous of p27Kip1 protein abundance in glomeruli of diabetic
reports exist on promitogenic factors and signaling path- animals, which apparently was because of hyperglycemia
ways in MCs, less is known about antimitogenic mecha- [46]. With regard to MC growth control in glomerular
nisms that are able to block MC proliferation and might disease, the available data indicate that TGF-b not only
be involved in the maintenance of MC quiescence in the mediates the deposition of ECM but also functions as
normal kidney and/or in the resolution of mesangioproli- a potent autocrine inhibitor of G1-phase progression.
ferative disease. TGF-b is a potent endogenous growth- Dependent on the type and phase of glomerular disease,
inhibitory factor with the capacity to counterbalance MC the effects of TGF-b could therefore contribute to the
mitogenesis; it is secreted by MCs and can act in an resolution of hypercellular disease or lead to MC hyper-
autocrine fashion [32]. Multiple studies of MCs in culture trophy, a pathologic phenotype associated with expan-
have confirmed the antimitogenic and ECM-promoting sion of the mesangium and, possibly, MC activation.
action of TGF-b [32–35]. Furthermore, in studies of ex-
perimental glomerular disease, TGF-b has been found to
MODULATION OF MESANGIAL CELLinduce both beneficial, antimitogenic, anti-inflammatory
GROWTH BY EXTRACELLULAR MATRIXeffects [36] and harmful fibrogenesis leading to glomeru-
lar scarring [37–39]. Data from Kitamura et al demon- The ECM represents a very heterogenous source of
molecular information that profoundly regulates cell be-strated that mesangial overexpression of active TGF-b1
by the use of MCs as a vector for gene delivery to the havior. Changes in the quantity and composition of the
mesangial ECM can directly affect MC biology; in turn,renal glomerulus reduced increased glomerular mitogen-
esis in anti-Thy1.1 nephritis, implying that TGF-b1 acts changes in the MC activation status may result in altered
ECM synthesis. Under normal conditions, mesangialas a suppressor of glomerular inflammation [36].
We have investigated nuclear regulatory events in- ECM compounds are synthesized and degraded in a bal-
anced manner because the integrity of glomerular matri-duced by TGF-b1 in MCs [35]. TGF-b1 abrogated mito-
genesis of cultured MCs stimulated by PDGF, epidermal ces is strictly maintained throughout adult life. However,
the loss of coordinated regulation with increase in mes-growth factor (EGF), serotonin, endothelin-1, or basic
fibroblast growth factor (bFGF). By FACS analysis, we angial ECM deposition occurs in the development of
glomerulosclerosis, a common feature of many forms ofobserved that the incubation of cultured MCs with TGF-
b1 blocks the progression of the MC cycle in the G1 chronic inflammatory glomerular disease.
Studies in the last decade have revealed that in addi-phase of the cell cycle. One of the molecular mechanisms
used by TGF-b1 to arrest MCs in G1 phase was the tion to soluble regulator molecules, nonsoluble ECM
compounds can also influence MC growth. In vitro,significantly diminished activation of cyclin E/cdk2-com-
plexes induced by PDGF. Subsequently, the decrease of freshly seeded MCs do not only plate with much higher
efficiency on collagen IV and fibronectin compared withcyclin E/cdk2 activity was reflected by less phosphoryla-
tion of the retinoblastoma tumor suppressor (pRb), a plastic, but also show greater replication activity [47].
Thrombospondin-1, an antiadhesive matricellular glyco-negative cell cycle regulator [35]. Deactivation of pRb
via phosphorylation by G1 phase CDKs is a required protein that promotes cell rounding and division in a
variety of cell types, also increases MC proliferation.step for successful G1-phase progression and S-phase
entry [40]. Furthermore, in immunoprecipitation experi- This effect might be mediated in part by up-regulation
of epidermal growth factor and PDGF secretion, which,ments we found that the presence of TGF-b1 prevented
the release of the CKI p27Kip1 from cyclin E/cdk2 com- in turn, can increase MC proliferation in an autocrine
manner [48]. Several investigators observed dose-depen-plexes in the presence of soluble mitogens (unpublished
results). This appears to be one molecular mechanism dent inhibition of MC proliferation by heparan sulfate
Scho¨cklmann et al: Regulation of MC proliferation 1205
[49, 50]. Furthermore, several proteoglycans are able The results of these studies indicate a direct growth-
promoting function of integrin-dependent shc signalingto bind and sequester various cytokines, for example,
TGF-b and bFGF. Local storage of such factors could in anchorage-dependent growth. Recently, caveolin-1
was identified as a membrane adaptor protein that linksrepresent an important regulatory function of glomerular
proteoglycans. Morita et al reported that heparan sulfate the integrin a chain to the tyrosine kinase c-fyn, which, in
turn, activates and binds shc [59]. Results of our currentproteoglycans show an enrichment of bFGF-binding do-
mains in fibrotic lesions of the peritubular interstitium studies have shown that these signaling molecules are
also operative and regulated in cultured MCs (unpub-[51]. Taken together, these results support the notion
that ECM molecules bind and sequester growth factors, lished observations). However, the precise nuclear sig-
naling events that mediate ECM effects to control quies-possibly providing a local “reservoir” of regulatory pro-
teins and presenting them to adjacent cells in a biologi- cence or proliferation of MCs remain to be clarified.
Stimulated by work performed in vascular smoothcally more active form. This concept, however, needs
experimental proof. muscle cells [62], we have recently tested the hypothesis
that type I collagen inhibits MC proliferation by modu-Several studies performed with fibroblasts have ex-
plored the molecular basis of anchorage-dependent cell lating cell cycle regulatory proteins of MCs in culture
[63]. Although type I collagen is not expressed in glomer-growth on the level of cell cycle regulators. Zhu et al
demonstrated that cell adhesion induces cyclin D1 uli of healthy kidneys, type I collagen accumulates in
the mesangial ECM in certain forms of glomerulonephri-mRNA and is required for cyclin E/cdk2 activation and
subsequent phosphorylation of pRb, an effect that is tis. In the turnover of ECM, type I collagen is constantly
degraded and structurally modified, for example, by pro-possibly mediated by down-regulation of the nuclear
CDK inhibitor proteins p21Waf-1 and p27Kip1 [52]. Similarly, teolytic enzymes. MCs have been shown to bind to native
type I collagen predominantly via a1b1 and a2b1 integrins.Fang et al showed that the cyclin E/cdk2 complex is
activated in attached fibroblasts, but not in fibroblasts As an in vitro system to study the effects of structurally
maintained in suspension [53]. These data establish a altered ECM molecules, we examined how two structur-
cell cycle basis to explain the combined requirement of ally distinct forms of type I collagen, monomer versus
both growth factors and ECM for anchorage-dependent polymerized fibrils, affect proliferation and expression
growth of cells that are in transit through the G1 phase of G1-phase regulators in MCs, using two-dimensional
and entry into the S phase. cell culture. The adhesion of MCs to monomer or poly-
In addition to the need of mere cell anchorage for merized collagen was similarly effective. However, in
proliferation, the pattern of expressed adhesion mole- contrast to control substratum of plastic or monomer
cules may also influence cell cycle progression. The ex- collagen, polymerized collagen completely prevented the
pression of integrin b1C, an alternatively spliced variant serum-induced increase of DNA synthesis and MC repli-
of b1 integrin, has been described to inhibit growth by cation. The inhibitory effect of polymerized type I colla-
blocking cell cycle progression in the late G1 phase in gen was characterized by the rapid down-regulation of
fibroblasts [54] and epithelial cells [55]. Recently, inte- cyclins D1 and E and the lack of serum-mediated sup-
grin b1C was identified as an upstream regulator of the pression of the CKI p27Kip1 [63]. We speculate that poly-
CKI p27Kip1: overexpression of integrin b1C was associ- merized type I collagen fibrils specifically regulate early
ated with induction of p27Kip1 protein levels, inhibition a1b1 or a2b1 integrin signaling, which leads to inhibition
of cyclin A-dependent kinase activity, and increased as- of MC proliferation. In cultured MCs, polymerized type
sociation of p27Kip1 with cyclin A [56]. Giancotti et al have I collagen also diminished c-fos induction and the activa-
examined mitogenic signaling mechanisms mediated by tion of various kinases involved in intracellular signaling
integrin receptors in endothelial cells and fibroblasts and events [64]. This study did not examine whether the
could identify pathways specific for subgroups of inte- ECM-driven cellular effects are regulated by integrin-
grins (discussed in F. Giancotti’s abstract in this Sympo- mediated signals.
sium issue). Although most integrins are capable of acti-
vating focal adhesion kinase upon attachment to ECM,
CONCLUSIONa1b1, a5b1, avb3, and a6b4 integrins are coupled to the ras-
Taken together, the control of quiescence, prolifera-ERK pathway via recruitment of the adaptor protein shc
tion, and survival of MCs greatly affects glomerular[57–59]. The shc adaptor links various tyrosine kinases
structure and function in normal or diseased kidneys.to ras by recruiting the Grb2/SOS complex to the cell
Some of the regulatory mechanisms that are operativemembrane [60]. In endothelial cells and keratinocytes,
in MCs in culture and in vivo have recently been clarified.ligation of integrins linked to shc enabled the progression
They involve multiple specific soluble or nonsoluble ex-through the G1 phase in response to soluble mitogens.
tracellular factors, and a complex array of receptor-medi-In contrast, ligation of other integrins resulted in growth
arrest, even in the presence of soluble mitogens [58, 61]. ated signals that control cell cycle progression as well as
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